For people living with post-traumatic stress disorder, nighttime can sometimes be harder than daytime.
Sleep may bring back frightening events in vivid dreams, causing people to wake terrified and leaving them exhausted the next morning.
These repeated nightmares can become a serious health problem of their own. Poor sleep can affect memory, concentration, mood and physical health, and some people with PTSD begin delaying bedtime because they are afraid of what will happen once they fall asleep.
PTSD develops after severe or threatening experiences, but not everyone who goes through trauma develops the disorder. When it does occur, the brain can remain highly sensitive to reminders of danger long after the original event has ended.
Treatment often includes specialized psychotherapy designed to help a person process traumatic memories safely. Medicines can also be useful, but nightmares are among the symptoms that may remain stubborn even when other areas improve.
A clinical trial from Charité — Universitätsmedizin Berlin has now found that a prescription form of THC may provide relief for some of these patients. The drug tested was Dronabinol, which contains tetrahydrocannabinol, one of the best-known compounds in cannabis.
THC acts on the endocannabinoid system, a natural communication network in the brain and body. This system is involved in sleep, stress responses, appetite, pain and the way emotional experiences are processed.
Scientists have long suspected that changing this system could affect dreaming. THC can alter sleep patterns and may reduce the intensity or frequency of dreams, including dreams that occur during rapid eye movement sleep.
Professor Stefan Röpke and his team wanted to know whether this effect could be useful rather than simply sedating. They recruited more than 170 people who had PTSD and frequent, severe trauma-related nightmares.
The participants entered a ten-week trial. Each evening they took either Dronabinol drops or a placebo with a similar appearance and flavor.
The trial was double blind, meaning neither the patients nor the clinicians assessing them knew who received THC during the study. This is an important strength because expectations can strongly influence reports of sleep, pain and emotional symptoms.
By the end of the trial, both groups had improved, but the change was larger among those receiving Dronabinol. Their average nightmare score fell by 3.7 points on an eight-point scale, compared with a 2.2-point reduction in the placebo group.
The individual responses were also notable. More than one-third of the Dronabinol group said their nightmares had disappeared completely after ten weeks.
A further 21% said their nightmare burden had fallen by at least half. About five out of six participants receiving the medicine felt that their health had clearly improved.
These results suggest that the treatment may be particularly helpful for the nighttime symptoms of PTSD. Researchers did not find equally clear evidence that it improved the entire disorder, including depression or the overall collection of PTSD symptoms.
That difference matters because better sleep does not necessarily mean that traumatic memories have been fully processed. Someone may still need psychotherapy and other forms of support even if nightmares become less frequent.
The researchers also paid close attention to side effects. No severe treatment-related problems were reported during the study, but dizziness, headaches and increased appetite were more common with Dronabinol than with placebo.
No clear withdrawal symptoms appeared after treatment stopped. Even so, ten weeks is a fairly short period when considering a medicine that may potentially be used for a chronic condition.
THC can affect thinking, coordination, mood and reaction time, and cannabis-related products also carry concerns about tolerance and dependence in some users. Future trials therefore need to examine whether the same dose remains effective and safe over much longer periods.
Another important caution is that the study examined a standardized prescription medicine. It does not show that smoking cannabis, using unregulated products or self-medicating with THC will provide the same benefit.
Prescription Dronabinol delivers a measured dose under medical supervision, while cannabis products can vary greatly in THC strength and may contain other compounds. Those differences make direct comparisons inappropriate.
The study also reminds us that sleep itself is an important treatment target in PTSD. Even when a medicine does not reduce every symptom, stopping repeated nighttime reliving of trauma could give some patients more stable sleep and improve their ability to function during the day.
The trial’s randomized, placebo-controlled design makes the findings encouraging, but they are not the final word. Longer studies are needed to confirm durability, identify which patients benefit most and establish the safest way to use the drug.
The research was published in Nature Medicine. If those later studies are successful, Dronabinol may eventually give doctors another targeted tool for people whose PTSD nightmares remain severe despite existing treatment.
If you care about mental health, please read studies about how dairy foods may influence depression risk, and 6 foods you can eat to improve mental health.
For more mental health information, please see recent studies about top foods to tame your stress, and Omega-3 fats may help reduce depression.
Source: Charité — Universitätsmedizin Berlin.
